Developer docs
API playgroundTry for free, no card

Search company profiles

Nobelpharma

Full company profile

uuid0009mvt

Namestring
Nobelpharma
Legal namestring
ノーベルファーマ株式会社 (Nobelpharma Co., Ltd.)
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Nobelpharma Co., Ltd. (ノーベルファーマ株式会社) is a privately held Japanese specialty pharmaceutical company founded in 2003 and headquartered in Tokyo's Chuo-ku district. The company's stated mission is to develop and provide pharmaceutical products and medical devices for rare diseases and unmet medical needs that larger pharmaceutical companies have overlooked. Its portfolio consists of approximately 15 approved prescription products spanning rare neurological conditions (neonatal convulsions, GNE myopathy, sleep disorders in neurodevelopmental disorders), rare pulmonary conditions (autoimmune pulmonary alveolar proteinosis, lymphangioleiomyomatosis, pleural effusion/pneumothorax), rare dermatological conditions (TSC skin lesions), rare women's health conditions (dysmenorrhea, endometriosis), rare neonatal conditions (apnea of prematurity), rare ENT conditions (spasmodic dysphonia, tympanic membrane perforation), and rare metabolic conditions (Wilson's disease, zinc deficiency). Key branded assets include Rapalimus (mTOR inhibitor in tablet and topical gel forms for TSC and LAM), Noverzin and Jintas (zinc-based therapies), Acenover (GNE myopathy), Salgran (APAP), and Melatobel (pediatric sleep disorders).

The company's underlying capability is pharmaceutical development and commercialization for orphan indications, rather than any specific platform technology. It operates a sales-led go-to-market model through a dedicated medical representative (MR) force targeting healthcare professionals, with disease-awareness portals (aendegenki.jp, nobelpark.jp, and condition-specific sub-sites) supporting physician and patient education. Products are distributed through major Japanese pharmaceutical wholesalers including Medipal Holdings, Mediceo, Aska Seiyaku, Atoru, Ebalus, Yoniyaku, Nakazawa-Yakugyo, and Higashishichi, and dispensed via prescription through hospitals and pharmacies.

Nobelpharma generates revenue primarily through prescription pharmaceutical sales in Japan, with prices set by the national health insurance reimbursement system and not publicly disclosed. The company has begun selective international commercialization, exporting products to China (Noverzin launched June 2026) and operating a wholly-owned US subsidiary (Nobelpharma America LLC) for cross-border operations and data-sharing. The company's CEO is Hitoshi Shiomura (塩村仁), and it has a headcount of 251-500 employees. Customer segments are healthcare professionals who prescribe orphan-disease therapies and the rare-disease patient populations they treat.

Short descriptiontext

Nobelpharma is a Japanese specialty pharmaceutical company that develops and commercializes orphan drugs for rare diseases and unmet medical needs, serving patients with conditions such as TSC, LAM, GNE myopathy, Wilson's disease, and APAP across Japan and select international markets including China.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersShinkawa, Japan
HQ citystring
Shinkawa
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
orphan drug development, rare disease pharmaceuticals, unmet medical needs, specialty therapeutics, prescription medicines
Industry5 codes
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAM
Rare Dermatology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals (Orphan Drugs)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Prescription Pharmaceutical Products
TypeOne Time License
Description

Nobelpharma generates revenue through the sale of prescription pharmaceutical products primarily in Japan, focusing on orphan drugs and treatments for rare diseases with limited competition.

nobelpharma.co.jp
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1NobelPark
Description

Product information portal for healthcare professionals featuring product details and medical information.

nobelpharma.co.jp
Core offering1 text field

Nobelpharma researches, develops, and commercializes prescription pharmaceutical products targeting rare diseases and unmet medical needs, with a focus on orphan drugs across therapeutic areas such as oncology, neurology, dermatology, and rare genetic conditions. The company sells its medicines through pharmaceutical wholesalers to hospitals, clinics, and pharmacies in Japan and selected international markets.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Nobelpharma is a Japanese pharmaceutical company focused on developing and providing medications for rare diseases and unmet medical needs. The company offers a portfolio of specialized pharmaceutical products across multiple therapeutic areas including: zinc deficiency treatments (Noverzin, Jintas), respiratory/pulmonary conditions (Salgran for APAP, Unitalc for pleural effusion, Rapalimus for LAM/TSC), neurological conditions (Noverbar/Fostoin for seizures, Melatobel for sleep disorders, Titan Bridge for voice disorders), dermatology (Rapalimus Gel for skin lesions), women's health (Lunabell, Jemina for dysmenorrhea/endometriosis), neonatal care (Respier for apnea of prematurity), ENT conditions (Ritympa for tympanic membrane), and rare genetic diseases (Acenover for GNE myopathy). Nobelpharma positions itself as addressing diseases that are often overlooked by other pharmaceutical companies, providing treatments for conditions such as tuberous sclerosis complex, lymphangioleiomyomatosis, and various orphan diseases.

Product and service12 records
1ノベルジン®錠25mg/50mg (Noverzin Tablet 25mg/50mg)
CategoryPrescription Pharmaceutical - Zinc Deficiency / Wilson's Disease
Description

Zinc deficiency treatment agent also used for Wilson's disease (hepatolenticular degeneration); available in 25mg and 50mg tablet formulations for healthcare providers.

2ジンタス®25㎎錠 (Jintas 25mg Tablet)
CategoryPrescription Pharmaceutical - Zinc Deficiency
Description

Zinc deficiency treatment agent indicated for hypozincemia; available as a 25mg tablet for prescription use.

3ラパリムス®錠 (Rapalimus Tablet)
CategoryPrescription Pharmaceutical - Rare Pulmonary / TSC
Description

mTOR inhibitor (sirolimus-based) tablet indicated for lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC) associated conditions in adults.

4ラパリムス®ゲル (Rapalimus Gel)
CategoryPrescription Pharmaceutical - Dermatology / TSC
Description

Topical sirolimus gel formulation for tuberous sclerosis complex (TSC) associated skin lesions (facial angiofibromas).

5ルナベル®配合錠LD (Lunabell LD Tablet)
CategoryPrescription Pharmaceutical - Women's Health
Description

Low-dose combined oral contraceptive tablet (ethinylestradiol/norethisterone) used for the treatment of dysmenorrhea and endometriosis.

6ジェミーナ (Jemina)
CategoryPrescription Pharmaceutical - Women's Health
Description

Low-dose combined oral contraceptive tablet indicated for the treatment of dysmenorrhea.

7レスピア (Respier)
CategoryPrescription Pharmaceutical - Neonatal Care
Description

Caffeine citrate formulation indicated for primary apnea of prematurity (immature infant apnea) in premature and low birth weight infants.

8チタンブリッジ (Titan Bridge)
CategoryMedical Device - ENT / Voice Disorder
Description

Medical device indicated for adductor type spasmodic dysphonia (ADSD), a voice disorder where the voice becomes stuck or interrupted when attempting to speak.

9リティンパ (Ritympa)
CategoryRegenerative Medicine - ENT
Description

Regenerative medicine product indicated for tympanic membrane perforation (persistent eardrum perforation).

10ユニタルク (Unitalc)
CategoryPrescription Pharmaceutical - Pulmonary / Oncology
Description

Talc-based medical product for the prevention of malignant pleural fluid re-accumulation or recurrent refractory secondary pneumothorax where surgical treatment is difficult.

11ノーベルバール (Noverbar)
CategoryPrescription Pharmaceutical - Neonatal Neurology
Description

Phenobarbital anticonvulsant indicated for the treatment of neonatal convulsions.

12ホストイン (Fostoin)
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMinorTypeOthersAnnounced on2026-04-23
Description

Both companies are identified as prominent players in the global tuberous sclerosis complex (TSC) market according to Research and Markets analysis. Nobelpharma is mentioned alongside Novartis in market research reports covering TSC treatments.

Strategic tierMinorTypeOthersAnnounced on2026-04-23
Description

Both companies are identified as prominent players in the global tuberous sclerosis complex (TSC) market according to Research and Markets analysis. Nobelpharma is mentioned alongside Jazz Pharmaceuticals in market research reports covering TSC treatments.

3Medipal Holdings
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Major pharmaceutical wholesale distribution partner in Japan. Medipal Holdings distributes Nobelpharma products to medical institutions and pharmacies throughout Japan as part of the company's distribution network.

nobelpharma.co.jp
4Mediceo
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Pharmaceutical wholesale distribution partner. Mediceo distributes Nobelpharma products as part of the pharmaceutical distribution network in Japan.

nobelpharma.co.jp
5Aska Seiyaku
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Pharmaceutical wholesale distribution partner and joint use partner for medical representative information sharing and distribution optimization.

nobelpharma.co.jp
Strategic tierCoreTypeOthers
Description

Wholly-owned subsidiary of Nobelpharma Co., Ltd. located in the United States. Engages in joint use of customer data with the parent company for pharmaceutical business operations.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global specialty pharmaceutical company with established rare disease franchises, explicitly identified alongside Nobelpharma as a prominent player in the global TSC market. Directly comparable in orphan-disease strategy and therapeutic-area focus.

TypeBroad incumbent
Description

Specialty pharmaceutical group with a dedicated rare-disease business unit marketing treatments for orphan indications globally. Comparable as a specialty pharma with orphan-disease franchise and similar European/global commercial profile.

3Nippon Shinyaku
TypeDirect peer
Description

Japanese specialty pharmaceutical company with a strong rare-disease focus, including treatments for genetic and orphan indications. Directly comparable as a Japan-based specialty pharma addressing unmet medical needs in similar therapeutic areas.

TypeBroad incumbent
Description

Rare-disease specialty pharmaceutical unit of AstraZeneca, focused on complement-mediated and other orphan conditions. Comparable as a rare-disease-focused commercial franchise operating within a larger parent — similar orphan-drug commercial model to Nobelpharma's.

TypeEmerging player
Description

Clinical and commercial-stage biopharmaceutical company focused exclusively on rare and ultra-rare genetic diseases. Comparable as a rare-disease specialist with overlapping therapeutic approaches to genetic and metabolic orphan conditions.

TypeBroad incumbent
Description

Global rare-disease specialty pharmaceutical company marketing therapies across genetic and orphan indications. Comparable business model of developing and commercializing drugs for small populations with high unmet need.

TypeBroad incumbent
Description

Global specialty pharmaceutical company whose strategy centers on rare and serious diseases (CF, sickle cell, pain). Comparable as a rare-disease-focused commercial-stage pharma, though materially larger and globally commercialized.

TypeBroad incumbent
Description

Identified alongside Nobelpharma as a prominent global TSC market player through its Afinitor franchise. A large diversified pharma incumbent with significant rare-disease presence that overlaps with Nobelpharma's core therapeutic areas.

TypeDirect peer
Description

Japanese specialty pharmaceutical company with oncology and rare-disease franchises. Comparable as a mid-to-large Japanese specialty pharma that has successfully built niche specialty franchises outside the mainstream pharma model.

10Mochida Pharmaceutical
TypeDirect peer
Description

Japanese specialty pharmaceutical company focused on niche therapeutic areas including rare diseases and specialty indications. Comparable as a Japanese mid-sized specialty pharma with orphan-disease products.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nobelpharma

Specialty Pharmaceuticals (Orphan Drugs)nobelpharma.co.jp

Nobelpharma is a Japanese specialty pharmaceutical company that develops and commercializes orphan drugs for rare diseases and unmet medical needs, serving patients with conditions such as TSC, LAM, GNE myopathy, Wilson's disease, and APAP across Japan and select international markets including China.

What Nobelpharma does

Nobelpharma Co., Ltd. (ノーベルファーマ株式会社) is a privately held Japanese specialty pharmaceutical company founded in 2003 and headquartered in Tokyo's Chuo-ku district. The company's stated mission is to develop and provide pharmaceutical products and medical devices for rare diseases and unmet medical needs that larger pharmaceutical companies have overlooked. Its portfolio consists of approximately 15 approved prescription products spanning rare neurological conditions (neonatal convulsions, GNE myopathy, sleep disorders in neurodevelopmental disorders), rare pulmonary conditions (autoimmune pulmonary alveolar proteinosis, lymphangioleiomyomatosis, pleural effusion/pneumothorax), rare dermatological conditions (TSC skin lesions), rare women's health conditions (dysmenorrhea, endometriosis), rare neonatal conditions (apnea of prematurity), rare ENT conditions (spasmodic dysphonia, tympanic membrane perforation), and rare metabolic conditions (Wilson's disease, zinc deficiency). Key branded assets include Rapalimus (mTOR inhibitor in tablet and topical gel forms for TSC and LAM), Noverzin and Jintas (zinc-based therapies), Acenover (GNE myopathy), Salgran (APAP), and Melatobel (pediatric sleep disorders).

The company's underlying capability is pharmaceutical development and commercialization for orphan indications, rather than any specific platform technology. It operates a sales-led go-to-market model through a dedicated medical representative (MR) force targeting healthcare professionals, with disease-awareness portals (aendegenki.jp, nobelpark.jp, and condition-specific sub-sites) supporting physician and patient education. Products are distributed through major Japanese pharmaceutical wholesalers including Medipal Holdings, Mediceo, Aska Seiyaku, Atoru, Ebalus, Yoniyaku, Nakazawa-Yakugyo, and Higashishichi, and dispensed via prescription through hospitals and pharmacies.

Nobelpharma generates revenue primarily through prescription pharmaceutical sales in Japan, with prices set by the national health insurance reimbursement system and not publicly disclosed. The company has begun selective international commercialization, exporting products to China (Noverzin launched June 2026) and operating a wholly-owned US subsidiary (Nobelpharma America LLC) for cross-border operations and data-sharing. The company's CEO is Hitoshi Shiomura (塩村仁), and it has a headcount of 251-500 employees. Customer segments are healthcare professionals who prescribe orphan-disease therapies and the rare-disease patient populations they treat.

Nobelpharma firmographics

Firmographics
Name
Nobelpharma
Legal name
ノーベルファーマ株式会社 (Nobelpharma Co., Ltd.)
Website
https://nobelpharma.co.jp
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
51–100 employees
Short description
Nobelpharma is a Japanese specialty pharmaceutical company that develops and commercializes orphan drugs for rare diseases and unmet medical needs, serving patients with conditions such as TSC, LAM, GNE myopathy, Wilson's disease, and APAP across Japan and select international markets including China.
Ownership category
akta.pro rank

Nobelpharma industry classification

Industry
Product category
Specialty Pharmaceuticals (Orphan Drugs)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAM
Rare Dermatology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Orphan drug development
  • Rare disease pharmaceuticals
  • Unmet medical needs
  • Specialty therapeutics
  • Prescription medicines

Where Nobelpharma is headquartered

Location

Headquarters

HQ city
Shinkawa
HQ country
Japan
HQ region
Asia

Offices1 record

Markets served

Nobelpharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. Prescription Pharmaceutical Products: Nobelpharma generates revenue through the sale of prescription pharmaceutical products primarily in Japan, focusing on orphan drugs and treatments for rare diseases with limited competition.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Nobelpharma product offering

Product offering

Core offering

Nobelpharma researches, develops, and commercializes prescription pharmaceutical products targeting rare diseases and unmet medical needs, with a focus on orphan drugs across therapeutic areas such as oncology, neurology, dermatology, and rare genetic conditions. The company sells its medicines through pharmaceutical wholesalers to hospitals, clinics, and pharmacies in Japan and selected international markets.

Product overview

Nobelpharma is a Japanese pharmaceutical company focused on developing and providing medications for rare diseases and unmet medical needs. The company offers a portfolio of specialized pharmaceutical products across multiple therapeutic areas including: zinc deficiency treatments (Noverzin, Jintas), respiratory/pulmonary conditions (Salgran for APAP, Unitalc for pleural effusion, Rapalimus for LAM/TSC), neurological conditions (Noverbar/Fostoin for seizures, Melatobel for sleep disorders, Titan Bridge for voice disorders), dermatology (Rapalimus Gel for skin lesions), women's health (Lunabell, Jemina for dysmenorrhea/endometriosis), neonatal care (Respier for apnea of prematurity), ENT conditions (Ritympa for tympanic membrane), and rare genetic diseases (Acenover for GNE myopathy). Nobelpharma positions itself as addressing diseases that are often overlooked by other pharmaceutical companies, providing treatments for conditions such as tuberous sclerosis complex, lymphangioleiomyomatosis, and various orphan diseases.

Differentiator

Problem solved

Functional benefit

Brands

  • NobelPark: Product information portal for healthcare professionals featuring product details and medical information.

Products and services

  • ノベルジン®錠25mg/50mg (Noverzin Tablet 25mg/50mg) Zinc deficiency treatment agent also used for Wilson's disease (hepatolenticular degeneration); available in 25mg and 50mg tablet formulations for healthcare providers.
  • ジンタス®25㎎錠 (Jintas 25mg Tablet) Zinc deficiency treatment agent indicated for hypozincemia; available as a 25mg tablet for prescription use.
  • ラパリムス®錠 (Rapalimus Tablet) mTOR inhibitor (sirolimus-based) tablet indicated for lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC) associated conditions in adults.
  • ラパリムス®ゲル (Rapalimus Gel) Topical sirolimus gel formulation for tuberous sclerosis complex (TSC) associated skin lesions (facial angiofibromas).
  • ルナベル®配合錠LD (Lunabell LD Tablet) Low-dose combined oral contraceptive tablet (ethinylestradiol/norethisterone) used for the treatment of dysmenorrhea and endometriosis.
  • ジェミーナ (Jemina) Low-dose combined oral contraceptive tablet indicated for the treatment of dysmenorrhea.
  • レスピア (Respier) Caffeine citrate formulation indicated for primary apnea of prematurity (immature infant apnea) in premature and low birth weight infants.
  • チタンブリッジ (Titan Bridge) Medical device indicated for adductor type spasmodic dysphonia (ADSD), a voice disorder where the voice becomes stuck or interrupted when attempting to speak.
  • リティンパ (Ritympa) Regenerative medicine product indicated for tympanic membrane perforation (persistent eardrum perforation).
  • ユニタルク (Unitalc) Talc-based medical product for the prevention of malignant pleural fluid re-accumulation or recurrent refractory secondary pneumothorax where surgical treatment is difficult.
  • ノーベルバール (Noverbar) Phenobarbital anticonvulsant indicated for the treatment of neonatal convulsions.
  • ホストイン (Fostoin)

Companies that use Nobelpharma

Customer profile

Segments2 records

Ideal customer profiles2 records

Nobelpharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Nobelpharma partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor and core.

  • NovartisminorOthers · 23 April 2026Both companies are identified as prominent players in the global tuberous sclerosis complex (TSC) market according to Research and Markets analysis. Nobelpharma is mentioned alongside Novartis in market research reports covering TSC treatments.
  • Jazz PharmaceuticalsminorOthers · 23 April 2026Both companies are identified as prominent players in the global tuberous sclerosis complex (TSC) market according to Research and Markets analysis. Nobelpharma is mentioned alongside Jazz Pharmaceuticals in market research reports covering TSC treatments.
  • Medipal HoldingscoreChannel Partner/ Reseller/ DistributorMajor pharmaceutical wholesale distribution partner in Japan. Medipal Holdings distributes Nobelpharma products to medical institutions and pharmacies throughout Japan as part of the company's distribution network.
  • MediceocoreChannel Partner/ Reseller/ DistributorPharmaceutical wholesale distribution partner. Mediceo distributes Nobelpharma products as part of the pharmaceutical distribution network in Japan.
  • Aska SeiyakucoreChannel Partner/ Reseller/ DistributorPharmaceutical wholesale distribution partner and joint use partner for medical representative information sharing and distribution optimization.
  • Nobelpharma America LLCcoreOthersWholly-owned subsidiary of Nobelpharma Co., Ltd. located in the United States. Engages in joint use of customer data with the parent company for pharmaceutical business operations.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Nobelpharma competitors and assessment

Company assessment

Direct peers

  • Jazz Pharmaceuticals: Global specialty pharmaceutical company with established rare disease franchises, explicitly identified alongside Nobelpharma as a prominent player in the global TSC market. Directly comparable in orphan-disease strategy and therapeutic-area focus.
  • Nippon Shinyaku: Japanese specialty pharmaceutical company with a strong rare-disease focus, including treatments for genetic and orphan indications. Directly comparable as a Japan-based specialty pharma addressing unmet medical needs in similar therapeutic areas.
  • Taiho Pharmaceutical: Japanese specialty pharmaceutical company with oncology and rare-disease franchises. Comparable as a mid-to-large Japanese specialty pharma that has successfully built niche specialty franchises outside the mainstream pharma model.
  • Mochida Pharmaceutical: Japanese specialty pharmaceutical company focused on niche therapeutic areas including rare diseases and specialty indications. Comparable as a Japanese mid-sized specialty pharma with orphan-disease products.

Broad incumbents

  • Recordati Rare Diseases: Specialty pharmaceutical group with a dedicated rare-disease business unit marketing treatments for orphan indications globally. Comparable as a specialty pharma with orphan-disease franchise and similar European/global commercial profile.
  • Alexion (AstraZeneca Rare Disease): Rare-disease specialty pharmaceutical unit of AstraZeneca, focused on complement-mediated and other orphan conditions. Comparable as a rare-disease-focused commercial franchise operating within a larger parent — similar orphan-drug commercial model to Nobelpharma's.
  • BioMarin Pharmaceutical: Global rare-disease specialty pharmaceutical company marketing therapies across genetic and orphan indications. Comparable business model of developing and commercializing drugs for small populations with high unmet need.
  • Vertex Pharmaceuticals: Global specialty pharmaceutical company whose strategy centers on rare and serious diseases (CF, sickle cell, pain). Comparable as a rare-disease-focused commercial-stage pharma, though materially larger and globally commercialized.
  • Novartis: Identified alongside Nobelpharma as a prominent global TSC market player through its Afinitor franchise. A large diversified pharma incumbent with significant rare-disease presence that overlaps with Nobelpharma's core therapeutic areas.

Emerging players

  • Ultragenyx Pharmaceutical: Clinical and commercial-stage biopharmaceutical company focused exclusively on rare and ultra-rare genetic diseases. Comparable as a rare-disease specialist with overlapping therapeutic approaches to genetic and metabolic orphan conditions.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Nobelpharma social profiles

Digital presence

Nobelpharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nobelpharma leadership team

Management profile

Number of profiles

Profiles1 record

Nobelpharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Nobelpharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nobelpharma M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nobelpharma

What does Nobelpharma do?

Nobelpharma researches, develops, and commercializes prescription pharmaceutical products targeting rare diseases and unmet medical needs, with a focus on orphan drugs across therapeutic areas such as oncology, neurology, dermatology, and rare genetic conditions. The company sells its medicines through pharmaceutical wholesalers to hospitals, clinics, and pharmacies in Japan and selected international markets.

Is Nobelpharma a public or private company?

Nobelpharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Nobelpharma founded?

Nobelpharma was founded in 2003. It employs 51 to 100 people.

Where is Nobelpharma based?

Nobelpharma is headquartered in Shinkawa, Japan, in the Asia region.

How does Nobelpharma make money?

One revenue line is on record: prescription Pharmaceutical Products.

Who are Nobelpharma's main competitors?

Direct peers on record are Jazz Pharmaceuticals, Nippon Shinyaku, Taiho Pharmaceutical and Mochida Pharmaceutical. Broad incumbents are Recordati Rare Diseases, Alexion (AstraZeneca Rare Disease), BioMarin Pharmaceutical, Vertex Pharmaceuticals and Novartis. Ultragenyx Pharmaceutical is listed as an emerging player.

Does Nobelpharma have an API?

No public API is recorded for Nobelpharma.

What industry is Nobelpharma in?

Nobelpharma's product category is Specialty Pharmaceuticals (Orphan Drugs). Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireTuberous Sclerosis Complex Market Research and Global Long-term Forecast Report 2026-2035 Featuring Prominent Players - Novartis, Jazz Pharmaceuticals, Nobelpharma AmericaResearch and Markets has released a global market analysis projecting substantial growth for the tuberous sclerosis complex (TSC) market from 2025 to 2035, driven by increased disease awareness, advancements in treatments such as everolimus and CBD, and regulatory support including orphan drug designations. North America leads the market due to high healthcare expenditure and FDA approvals, while Asia-Pacific, particularly Japan and China, is identified as a rapidly growing region. Key market challenges include high treatment costs and safety concerns associated with long-term use of mTOR inhibitors.GlobeNewswireY-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate DevelopmentsY-mAbs reported Q3 2024 net product revenues of $18.5 million, down 10% year-over-year, and reiterated full-year 2024 guidance. The company entered an exclusive Japan license with Nobelpharma for $2.0 million upfront and extended its DANYELZA patent through February 2034.PR NewswireHYFTOR™ (sirolimus topical gel) 0.2%, the first FDA-approved topical treatment for facial angiofibroma associated with tuberous sclerosis, is now available in the USNobelpharma America, LLC has launched HYFTOR™ (sirolimus topical gel) 0.2% in the United States, making it the first and only FDA-approved topical treatment for facial angiofibroma associated with tuberous sclerosis complex (TSC), following the March 2022 regulatory approval. The medication is now available by prescription for adults and children 6 years of age and older through a limited network of specialty pharmacies equipped for cold storage requirements. The company states this launch represents a landmark event for the TSC community and marks Nobelpharma America's entry into the U.S. pharmaceutical market.PR NewswireFDA approves Nobelpharma's HYFTOR™ (sirolimus topical gel) 0.2%The FDA approved HYFTOR (sirolimus topical gel) 0.2% as the first topical treatment for facial angiofibroma associated with tuberous sclerosis complex in adults and children 6 years and older. The approval carries Orphan Drug status, and the drug is expected to be available in the U.S. in coming months.NatureSmall pharma takes a rare approach to treat neglected diseasesNobelpharma, a Japanese small pharma, focuses on developing orphan drugs for neglected rare diseases, having secured 15 new drug approvals by 2020. The company reports 16.9 billion yen in annual sales and is conducting a malaria vaccine trial in Burkina Faso.PR NewswireMalaria Vaccines Market to Surge Past US$ 591.8 Million by 2024 on the Back of Increasing Government and Non-Government Initiatives Towards Developing Vaccines: as per a New Business Report From CoherAccording to a market research report by Coherent Market Insights published in April 2017, the global malaria vaccines market is projected to expand at a compound annual growth rate (CAGR) of 102.8%, reaching approximately US$ 591.8 million by 2024 from US$ 8.5 million in 2018. The report identifies key drivers including the high malaria burden worldwide, with over 214 million cases and 438,000 deaths reported by WHO in 2015, and increasing government and non-government initiatives to develop vaccines, such as GSK's 2016 announcement to develop vaccines at a 5% profit margin. Major players identified in the market include GlaxoSmithKline plc, Sanaria Inc, Nobelpharma Co., Ltd., Sumaya Biotech, and GenVec, Inc., with Sub-Saharan Africa and Asia Pacific representing the highest disease burden regions.